- Home
- KZIA vs PMN Comparison
KZIA vs PMN Comparison
Compare KZIA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | PMN |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 115.5M |
| IPO Year | 2002 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KZIA | PMN |
|---|---|---|
| Price | $11.34 | $9.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $19.50 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 194.9K | 19.6K |
| Earning Date | 06-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $0.29 |
| 52 Week High | $17.40 | $27.40 |
Technical Indicators
Market Signals| Indicator | KZIA | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 39.34 |
| Support Level | $5.62 | $9.31 |
| Resistance Level | $14.57 | $11.37 |
| Average True Range (ATR) | 1.07 | 0.66 |
| MACD | -0.29 | -0.02 |
| Stochastic Oscillator | 21.55 | 26.37 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.